Ranbaxy (thailand) Co., Ltd. Pharmaceutical Import Profile — Thailand (DGFT 2022–2026)

Name: Ranbaxy (thailand) Co., Ltd. Pharmaceutical Import Records from India — 3 Products, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ranbaxy (thailand) Co., Ltd. — Pharmaceutical Importer Profile (2026) | 3 Products, $1.6M Trade | TransData Nexus

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sodium	Nutritional Supplements	$850.0K	17	0.2%	9
2	Chloroquine	Antimalarial & Antiparasitic	$400.0K	8	0.2%	9
3	Hydroxychloroquine	Antimalarial & Antiparasitic	$400.0K	8	0.3%	6

Ranbaxy (thailand) Co., Ltd. imports 3 pharmaceutical products across 2 categories into Thailand totaling $1.6M.

Ranbaxy (thailand) Co., Ltd. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ranbaxy (Thailand) Co., Ltd. is a pharmaceutical importer and distributor based in Bangkok, Thailand. Established in 2013, the company operates as a subsidiary of Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company. Sun Pharma acquired Ranbaxy Laboratories Limited in 2014, integrating its operations into the Sun Pharma group. Ranbaxy (Thailand) Co., Ltd. focuses on importing and distributing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, sourced primarily from India. The company's product portfolio spans various therapeutic areas, such as anti-infectives, gastrointestinals, neuro-psychiatry, cardiology, respiratory, orthopaedics, gynaecology, oncology, pain management, and over-the-counter (OTC) segments.

2Distribution Network

Ranbaxy (Thailand) Co., Ltd. operates from its office located at No. 475 Siripinyo Building, 8th Floor, Sri Ayutthaya Road, Phayathai Road, Ratchathewi, Bangkok 10400, Thailand. While specific details about the company's warehouse locations and logistics capabilities are not publicly disclosed, it is known that Ranbaxy (Thailand) Co., Ltd. imports finished pharmaceutical formulations from India. The company's distribution network is likely designed to ensure efficient delivery of these products across Thailand, leveraging both domestic and international logistics channels.

3Industry Role

Ranbaxy (Thailand) Co., Ltd. serves as a pharmaceutical importer and distributor within Thailand's pharmaceutical supply chain. By sourcing finished pharmaceutical formulations from India, the company plays a crucial role in ensuring the availability of a diverse range of medications in the Thai market. Its operations encompass the importation, storage, and distribution of these products to various healthcare providers, including hospitals, clinics, and pharmacies, thereby contributing to the accessibility of essential medicines in Thailand.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ranbaxy (thailand) Co., Ltd.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ranbaxy (Thailand) Co., Ltd. imports a limited range of products from India, with a total import value of $1.6 million USD across 33 shipments, covering three products in two therapeutic categories. The top three products imported are Sodium ($850K), Chloroquine ($400K), and Hydroxychloroquine ($400K), with the top five products accounting for 100% of the company's imports. This indicates a high level of sourcing concentration, which could pose risks related to supply chain disruptions or changes in supplier relationships. However, the strategic choice to focus on a narrow product range may also allow for specialized expertise and streamlined operations within these therapeutic areas.

2Supply Chain Resilience

The resilience of Ranbaxy (Thailand) Co., Ltd.'s supply chain is closely tied to its sourcing strategy from India. Given the company's concentrated import portfolio, any disruptions in the Indian supply chain—such as regulatory changes, manufacturing issues, or logistical challenges—could significantly impact product availability in Thailand. The company's reliance on a limited number of suppliers may also affect its ability to adapt to market fluctuations or demand shifts. To enhance supply chain resilience, Ranbaxy (Thailand) Co., Ltd. may consider diversifying its supplier base and exploring alternative sourcing options.

Importing Pharmaceuticals into Thailand — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Thailand

1Regulatory Authority & Framework

In Thailand, the Food and Drug Administration (FDA) under the Ministry of Public Health is the primary regulatory authority overseeing the importation, production, and distribution of pharmaceutical products. The Thai FDA enforces the Drug Act B.E. 2510 (1967), which sets standards and regulations for drug quality control. This legislation requires that all pharmaceutical products, including finished formulations, undergo a registration process with the Thai FDA before they can be manufactured, imported, or distributed within the country. (en.fda.moph.go.th)

2Import Licensing & GMP

Importing pharmaceutical products into Thailand necessitates obtaining an import license from the Thai FDA. Additionally, the Thai FDA requires that imported pharmaceutical products comply with Good Manufacturing Practice (GMP) standards. GMP certification from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), is typically accepted by the Thai FDA. This ensures that imported products meet the required quality standards for safety and efficacy. (en.fda.moph.go.th)

3Quality & Labeling

Ranbaxy (thailand) Co., Ltd. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ranbaxy (Thailand) Co., Ltd. focuses on importing finished pharmaceutical formulations in the therapeutic areas of nutritional supplements and antimalarial & antiparasitic drugs. The company's import data indicates that 51.5% of its imports are in the nutritional supplements category, while 48.5% are in the antimalarial & antiparasitic category. This strategic focus suggests a commitment to addressing specific health concerns prevalent in Thailand, such as nutritional deficiencies and malaria. The demand for these products is likely driven by the country's healthcare needs and the effectiveness of these medications in treating and preventing related health issues.

2Sourcing Profile

Ranbaxy (Thailand) Co., Ltd. sources generic pharmaceutical products from India, focusing on finished formulations rather than active pharmaceutical ingredients (APIs) or bulk drugs. This sourcing strategy allows the company to leverage India's established pharmaceutical manufacturing capabilities and cost advantages. By importing finished products, Ranbaxy (Thailand) Co., Ltd. can offer a diverse range of medications to the Thai market without the complexities associated with API sourcing and formulation.

3Market Positioning

Seller's Guide — How to Become a Supplier to Ranbaxy (thailand) Co., Ltd.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Ranbaxy (Thailand) Co., Ltd., especially if they can offer products that complement or expand the company's existing portfolio. Potential gaps in Ranbaxy (Thailand) Co., Ltd.'s current sourcing may include therapeutic areas not currently covered or specific formulations that are in demand but not yet available. By identifying these gaps and offering suitable products, new suppliers can establish partnerships and gain access to the Thai pharmaceutical market through Ranbaxy (Thailand) Co., Ltd.'s distribution network.

2Requirements & Qualifications

Indian exporters seeking to supply Ranbaxy (Thailand) Co., Ltd. and the broader Thai market must ensure that their products comply with the Thai FDA's regulations. This includes obtaining the necessary import licenses, ensuring GMP certification from recognized authorities, and adhering to labeling and quality control standards. Additionally, products must meet batch testing and stability requirements as mandated by the Thai FDA. Compliance with these standards is essential for successful market entry and distribution in Thailand. (en.fda.moph.go.th)

How to Approach

Frequently Asked Questions — Ranbaxy (thailand) Co., Ltd.

What products does Ranbaxy (thailand) Co., Ltd. import from India?

Ranbaxy (thailand) Co., Ltd. imports 3 pharmaceutical products across 2 categories. Top imports: Sodium ($850.0K), Chloroquine ($400.0K), Hydroxychloroquine ($400.0K).

What is Ranbaxy (thailand) Co., Ltd.'s total pharmaceutical import value?

Ranbaxy (thailand) Co., Ltd.'s total pharmaceutical import value from India is $1.6M, based on 33 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ranbaxy (thailand) Co., Ltd. focus on?

Ranbaxy (thailand) Co., Ltd. imports across 2 categories. The largest: Nutritional Supplements (51.5%), Antimalarial & Antiparasitic (48.5%).

Get Full Ranbaxy (thailand) Co., Ltd. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Ranbaxy (thailand) Co., Ltd.

Ranbaxy (thailand) Co., Ltd. — Import Portfolio & Supplier Network

What Products Does Ranbaxy (thailand) Co., Ltd. Import?

Top Products by Import Value

Ranbaxy (thailand) Co., Ltd. Therapeutic Categories — 2 Specializations